Hans‐Theodor Eich

923 total citations
27 papers, 631 citations indexed

About

Hans‐Theodor Eich is a scholar working on Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Surgery. According to data from OpenAlex, Hans‐Theodor Eich has authored 27 papers receiving a total of 631 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 15 papers in Pathology and Forensic Medicine and 7 papers in Surgery. Recurrent topics in Hans‐Theodor Eich's work include Lymphoma Diagnosis and Treatment (15 papers), Lung Cancer Treatments and Mutations (15 papers) and Head and Neck Cancer Studies (4 papers). Hans‐Theodor Eich is often cited by papers focused on Lymphoma Diagnosis and Treatment (15 papers), Lung Cancer Treatments and Mutations (15 papers) and Head and Neck Cancer Studies (4 papers). Hans‐Theodor Eich collaborates with scholars based in Germany, Switzerland and Austria. Hans‐Theodor Eich's co-authors include Martin Scheer, Volker Diehl, Matthias Kreppel, Uta Drebber, Joachim E. Zöller, Andreas Engert, Rolf‐Peter Müller, Heinz Haverkamp, Peter Borchmann and R. Semrau and has published in prestigious journals such as Journal of Clinical Oncology, Blood and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Hans‐Theodor Eich

26 papers receiving 622 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hans‐Theodor Eich Germany	14	393	245	244	176	100	27	631
Siddhartha Laskar India	17	276 0.7×	361 1.5×	340 1.4×	149 0.8×	185 1.9×	56	818
Yoshio Tamaki Japan	14	296 0.8×	161 0.7×	233 1.0×	96 0.5×	197 2.0×	48	637
Koichi Isobe Japan	16	351 0.9×	218 0.9×	284 1.2×	253 1.4×	240 2.4×	47	866
Sunao Tokumaru Japan	18	141 0.4×	348 1.4×	179 0.7×	153 0.9×	306 3.1×	54	842
Alicia Zhang United States	11	293 0.7×	156 0.6×	621 2.5×	57 0.3×	86 0.9×	16	851
Christine Landmann Switzerland	9	271 0.7×	138 0.6×	306 1.3×	134 0.8×	155 1.6×	23	763
Chung T. Chung United States	16	140 0.4×	231 0.9×	146 0.6×	134 0.8×	209 2.1×	38	669
Christian Ruebe Germany	14	235 0.6×	324 1.3×	199 0.8×	119 0.7×	116 1.2×	36	732
Ahitagni Biswas India	14	195 0.5×	113 0.5×	138 0.6×	126 0.7×	106 1.1×	88	628
Michael Tomé United States	13	193 0.5×	143 0.6×	208 0.9×	70 0.4×	216 2.2×	24	620

Countries citing papers authored by Hans‐Theodor Eich

Since Specialization

Citations

This map shows the geographic impact of Hans‐Theodor Eich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans‐Theodor Eich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans‐Theodor Eich more than expected).

Fields of papers citing papers by Hans‐Theodor Eich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hans‐Theodor Eich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans‐Theodor Eich. The network helps show where Hans‐Theodor Eich may publish in the future.

Co-authorship network of co-authors of Hans‐Theodor Eich

This figure shows the co-authorship network connecting the top 25 collaborators of Hans‐Theodor Eich. A scholar is included among the top collaborators of Hans‐Theodor Eich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans‐Theodor Eich. Hans‐Theodor Eich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Assaf, Chalid, Nina Booken, Edgar Dippel, et al.. (2024). Practical recommendations for therapy and monitoring of mogamulizumab patients in Germany. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 23(3). 341–354. 3 indexed citations

Borchmann, Peter, Alden A. Moccia, Richard Greil, et al.. (2024). Tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma: GHSG HD21, a randomized study.. Journal of Clinical Oncology. 42(17_suppl). LBA7000–LBA7000. 4 indexed citations

Ferdinandus, Justin, Katrin Roth, Markus Dietlein, et al.. (2023). Patterns of PET-positive residual tissue at interim restaging and risk of treatment failure in advanced-stage Hodgkin’s lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgkin Study Group. European Journal of Nuclear Medicine and Molecular Imaging. 51(2). 490–495. 4 indexed citations

Eichenauer, Dennis A., Christian Baues, Carsten Kobe, et al.. (2023). Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies. Blood. 142(6). 553–560. 6 indexed citations

Dirksen, Uta, Andreas Ranft, Daniel Baumhoer, et al.. (2021). Association of treatment delays with an unfavorable outcome in patients with localized Ewing sarcoma: A retrospective analysis of data from the GPOH Euro-E.W.I.N.G.99 trial.. Journal of Clinical Oncology. 39(15_suppl). 11502–11502. 3 indexed citations

Baues, Christian, Helen Goergen, Michael Fuchs, et al.. (2019). Consolidating Involved Field Radiotherapy Prevents Early and Local Recurrences in Early Stage Hodgkin Lymphoma. International Journal of Radiation Oncology*Biology*Physics. 105(1). S32–S33. 2 indexed citations

Kobe, Carsten, Georg Kuhnert, Deniz Kahraman, et al.. (2014). Assessment of Tumor Size Reduction Improves Outcome Prediction of Positron Emission Tomography/Computed Tomography After Chemotherapy in Advanced-Stage Hodgkin Lymphoma. Journal of Clinical Oncology. 32(17). 1776–1781. 44 indexed citations

Eich, Hans‐Theodor, Gabriele Reinartz, Carsten Kobe, et al.. (2013). Relapse Analysis After Radiation Therapy of PET-Positive Residual Tumors of Patients With Advanced Stage Hodgkin Lymphoma Treated in the HD15 Trial of the German Hodgkin Study Group (GHSG). International Journal of Radiation Oncology*Biology*Physics. 87(2). S5–S6. 1 indexed citations

Kreppel, Matthias, Hans‐Theodor Eich, Timo Dreiseidler, et al.. (2012). Preoperative vs. postoperative radiochemotherapy in patients with N2 squamous cell carcinoma of the oral cavity. Oral Oncology. 48(10). 1019–1024. 9 indexed citations

10.

Kreppel, Matthias, Timo Dreiseidler, Daniel Rothamel, et al.. (2012). The role of clinical versus histopathological staging in patients with advanced oral squamous cell carcinoma treated with neoadjuvant radiochemotherapy followed by radical surgery. Journal of Cranio-Maxillofacial Surgery. 41(1). 22–27. 38 indexed citations

11.

Marková, Jana, Deniz Kahraman, Carsten Kobe, et al.. (2011). Role of [18F]-fluoro-2-deoxy-d-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone. Leukemia & lymphoma. 53(1). 64–70. 39 indexed citations

12.

Kreppel, Matthias, Uta Drebber, Hans‐Theodor Eich, et al.. (2011). Combined-modality treatment in advanced oral squamous cell carcinoma. Strahlentherapie und Onkologie. 187(9). 555–560. 28 indexed citations

13.

Kreppel, Matthias, Uta Drebber, Inga Wedemeyer, et al.. (2011). Podoplanin expression predicts prognosis in patients with oral squamous cell carcinoma treated with neoadjuvant radiochemotherapy. Oral Oncology. 47(9). 873–878. 36 indexed citations

14.

Kreppel, Matthias, Uta Drebber, Daniel Rothamel, et al.. (2010). Prognostic impact of different TNM‐based stage groupings for oral squamous cell carcinoma. Head & Neck. 33(10). 1467–1475. 28 indexed citations

15.

Köcher, Martin, Sabine Kunze, Hans‐Theodor Eich, R. Semrau, & Rolf‐Peter Müller. (2005). Efficacy and Toxicity of Postoperative Temozolomide Radiochemotherapy in Malignant Glioma. Strahlentherapie und Onkologie. 181(3). 157–163. 38 indexed citations

16.

Köcher, Martin, et al.. (2005). Phase I/II Trial of Simultaneous Whole-Brain Irradiation and Dose-Escalating Topotecan for Brain Metastases. Strahlentherapie und Onkologie. 181(1). 20–25. 22 indexed citations

17.

Klimm, Beate, Andreas Engert, Corinne Brillant, et al.. (2005). Comparison of BEACOPP and ABVD chemotherapy in intermediate stage Hodgkin’s lymphoma: Results of the fourth interim analysis of the HD 11 trial of the GHSG. Journal of Clinical Oncology. 23(16_suppl). 6507–6507. 14 indexed citations

18.

Eich, Hans‐Theodor, Uwe Haverkamp, Andreas Engert, et al.. (2004). Biophysical analysis of acute toxicity of radiotherapy in Hodgkin’s lymphoma — a comparison between extended field and involved field radiotherapy based on the data of the german hodgkin study group (GHSG). International Journal of Radiation Oncology*Biology*Physics. 60(1). S219–S219.

19.

Ballová, Veronika, Jens Ulrich Rüffer, Heinz Haverkamp, et al.. (2004). A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Annals of Oncology. 16(1). 124–131. 109 indexed citations

20.

Eich, Hans‐Theodor, et al.. (2001). The role of postoperative radiotherapy in the management of merkel cell carcinoma. European Journal of Cancer. 37. S199–S199. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact